Children do not need to wear a patch all day

Article

There is no need for children with lazy eye to wear an eye patch for the whole day, in order to correct their vision, according to report published online by the British Medical Journal.

There is no need for children with lazy eye to wear an eye patch for the whole day, in order to correct their vision, according to report published online by the British Medical Journal.

Catherine Stewart and colleagues from City University, London, UK and McGill University, Montreal, Canada enrolled 80 children with amblyopia associated with strabismus, anisometropia or both, to wear glasses for 18 weeks followed by occlusion prescribed patching for either six (n=40) or 12 (n=40) hours a day.

The mean change in visual acuity (VA) was not significantly different between the two groups (p=0.64). The mean dose rates were also not significantly different (p=0.06). Visual outcomes were similar in children receiving patching three to six hours a day or more than six to 12 hours a day, but significantly better than in children who received less than three hours a day. Children aged four years or younger, required significantly less occlusion than older children and the visual outcome was not influenced by type of amblyopia.

The authors concluded that substantial (six hours a day) and maximal (12 hours) prescribed occlusion results in similar visual outcomes, suggesting that children do not need to wear the patch for a whole day in order to correct their vision.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.